Trending Now

Tribeca Capital Group, LLC Announces Expansion for New Year 2021 Mass Tort Initiative

Litigation Funding leader Tribeca Capital Group, LLC, is pleased to announce its New Year 2021 Mass Tort initiative to offer financial relief to victims of defective surgical implants, unsafe medications, or institutions that protected sexual predators. These mass torts include the over-the-counter heartburn medication Zantac, medical device placement surgeries for hernia mesh and inferior vena cava (IVC) filters, and sexual abuse by leaders and others associated with the Boy Scouts of America organization. Tribeca has formed a dedicated team to assist victims who are asserting claims against the corporations and groups in whom they placed their trust but ended up wreaking havoc in their lives.

According to Donadio, each year tens of thousands of people assert claims in mass tort litigation and class action lawsuits. Those matters often take two to three years before the parties reach a settlement, and even longer for the class members to be identified, claims filed and approved, and payment made. “We intend to offer financial assistance to as many claimants as possible now while they’re waiting for their claims to wind through litigation,” explains Tribeca founder Rory Donadio. “2020 was a horrendous year for so many. We want to do our part to help some of the folks who have been hit not only by the pandemic, but by these unscrupulous companies and organizations.”

Tribeca’s founder also emphasizes that these advances are not loans and are not designed to be repaid by the claimant. The litigation funding company takes its share from the eventual award. Even If the claimant’s award is less than the advance, the claimant owes Tribeca nothing.

Tribeca is fully prepared to handle the influx of new clients seeking financial assistance. The process is simple. Mass tort claimants can apply directly from the Tribeca website at tribecalawsuitloans.com or call (866) 388-2288. Donadio assures that Tribeca can process applications and make a funding offer within days. “Tribeca is thrilled to have an opportunity to help ease the burdens of people fighting for justice in these cases. Since we opened our doors, we have served more than twenty-five thousand clients by financing their litigation efforts and allowing them to receive a portion of their just due when they need it rather than having to wait the months and years that mass tort litigation often takes,” says Donadio.

If you are a claimant in one of these cases or a plaintiff in another type of personal-injury matter, a five-minute application or phone call can start the process for you. Call Tribeca Capital Group, LLC at (866) 388-2288 or visit our website at tribecalawsuitloans.com.

Announcements

View All

Victory Park Expands Legal Credit Leadership with Maleson Promotion

By John Freund |

Victory Park Capital (VPC), a global alternative asset manager specializing in private credit, has announced that Justin Maleson will expand his role to Managing Director, co-heading the firm’s legal credit investment strategy. The promotion underscores VPC’s ongoing investment in its legal finance capabilities and follows Maleson’s initial appointment in 2024 as Assistant General Counsel.

An announcement from Victory Park Capital details Maleson’s new responsibilities, which include sourcing, analyzing, and managing investments across legal assets, while maintaining oversight of the firm’s legal operations. He joins Chad Clamage in co-leading the strategy, working alongside team members Hugo Lestiboudois and Andrew Pascal, under the continued oversight of VPC CEO and founder Richard Levy.

Maleson brings a strong background in litigation finance and commercial law to the position. Before joining VPC, he served as a director at Longford Capital, where he specialized in originating and managing litigation funding transactions. His earlier tenure as a litigation partner at Jenner & Block further deepened his exposure to complex legal matters, equipping him with the expertise needed to navigate the nuanced legal credit space.

VPC’s legal credit team emphasizes an asset-backed lending model, prioritizing downside protection and predictable income streams. The firm aims to capitalize on inefficiencies within the legal funding market by leveraging its internal expertise and broad network of relationships. With Maleson’s appointment, VPC signals its intent to further scale its legal credit strategy, positioning itself as a key player in the evolving legal finance sector.

Maleson’s elevation comes at a time of increasing sophistication in litigation finance, where experienced legal minds are playing a pivotal role in portfolio construction and risk management. As VPC bolsters its leadership, the move may foreshadow further institutionalization of legal asset investing and heightened competition in a maturing market segment.

Golden Pear Upsizes Corporate Note to $78.7M Amid Growth Plans

By John Freund |

Golden Pear Funding has extended and upsized its investment-grade corporate note to $78.7 million, further bolstering the firm's capacity to serve the expanding litigation finance sector. The New York-based funder, a national leader in both pre-settlement and medical receivables financing, said the proceeds will support working capital and fuel strategic growth initiatives.

A press release from Golden Pear outlines how the capital raise reflects continued investor confidence in the firm’s business model. CEO Gary Amos noted that the infusion is critical as Golden Pear seeks to scale alongside the “rapidly expanding litigation finance market.” CFO Daniel Amsellem added that the new funding aligns with the company’s capital allocation strategy, aimed at optimizing operational efficiency and executing strategic projects.

Brean Capital, LLC acted as the exclusive financial advisor and sole placement agent on the transaction.

Founded in 2008, Golden Pear has funded more than $1.1 billion to over 87,000 clients and remains one of the largest specialty finance companies in the U.S. Its business model spans legal case funding and medical receivables purchasing, with backing from a network of private equity partners that provide institutional support for continued expansion.

LionFish Updates Model Documents in Response to CJC Report

By John Freund |

LionFish Litigation Finance Ltd has released a new suite of model litigation funding documents, updating its original set from February 2021. The revision comes on the heels of the Civil Justice Council's (CJC) Final Report on Litigation Funding, issued on 2 June 2025, which calls for a regulatory structure informed by best practices, including key principles published by the European Law Institute (ELI) in October 2024.

A LionFish press release details that the updated suite incorporates several of the ELI Principles (notably 4-12) and broader CJC recommendations, except where doing so would require legislative or procedural reform. LionFish's goal, according to Managing Director Tets Ishikawa, is not to dictate market norms but to foster industry-wide standardisation and efficiency. This proactive move is also intended to spark further collaboration between funders, insurers, and legal practitioners to develop trade practices akin to those in mature financial markets, such as those promoted by the Loan Market Association and the International Swaps and Derivatives Association.

The new suite includes three core documents: a litigation funding agreement, a priorities deed to define proceeds distribution, and an assignment deed for insurance benefits. Notably, LionFish has also added documentation for co-investment arrangements, reflecting a growing trend in syndicated funding deals. The funder has already closed seven such transactions.

Managing Director Tanya Lansky emphasised that while litigation funding remains complex, making documentation public enhances transparency and facilitates quicker deal closings—an essential factor for sustaining market growth.

As litigation finance continues to mature, this move by LionFish highlights a shift toward professionalisation and standardisation. With regulators increasingly focused on transparency and fairness, such initiatives may set a de facto benchmark for others in the industry. The question remains: will other funders follow suit, or will regulatory mandates be needed to compel alignment?